Synopsis: Wockhardt Ltd shares rally 37% in the last two days after FDA approval of ZAYNICH™ for cUTI, which showed 89% cure vs 68.4% with meropenem in Phase 3 ENHANCE-1, with QIDP/Fast Track status and global filings underway. The shares of a Mid-Cap company...
Synopsis: Healthcare stock surged 12 percent after FY26 results, driven by strong biotech growth, emerging market expansion, margin improvement, and a turnaround in profitability to Rs 199 crore PAT. The share of this company, which focuses on pharmaceutical...
Synopsis: Wockhardt Ltd surged 20% after the US FDA accepted its NDA for Zaynich, a first-in-class antibiotic with Fast Track designation, marking a historic milestone for the company and Indian pharmaceutical innovation. The shares of this global pharmaceutical...
The shares of the pharmaceutical company specializing in the pharmaceutical and biotechnology sectors, focusing on the research, development, manufacturing, and marketing, are in focus as the stock has rallied upto 19 percent in the day’s trade. In this article, let’s...
Synopsis: Wockhardt is exiting the US generics market after sustained losses to focus on antibiotics and insulin biologics. This strategic shift aims to drive innovation, profitability, and long-term growth across global markets. During Monday’s trading session,...
The Contract Development and Manufacturing Organization (CDMO) sector involves companies that provide services to help other businesses develop and manufacture pharmaceutical products. They handle tasks like drug development, production, and packaging for various...
The shares of this small cap pharmaceutical stock, involved in the production of finished dosage forms, like injectables and oral drugs hit 10 percent upper circuit on Friday after the company announced its new antibiotic has set a record-breaking success in Phase III...
